The technical language and the origin as a breast cancer drug obscures this, but an orally-active anti-interferon drug with no significant side effects is effectively a cure for the common cold. I don't expect much early attention to this, but it says something about ultimate market potential.
Science: initial response to a viral infection is through the "innate immunity" pathway. Part of this is secretion of chemicals that "wake up" the rest of the immune system, most importantly the interferons. Early cold symptoms are reactions to interferon. By the time a person feels sick, "adaptive immunity" is ready to take over from the innate pathway, so turning down the innate stuff isn't over-risky (although adaptive immunity does also use some signals that also cause a feeling of illness).